Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Sullivan

Showing results (101-110 of 130) with videos related to

Pageof 13
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 28, 2010
A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxisJanelle Perkins, Teresa Field, Jongphil Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2007
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational studyPamela Münster, Douglas Marchion, Elona Bicaku, et al.
BMJ Open|October 18, 2017
Health-related quality of life variations by sociodemographic factors and chronic conditions in three metropolitan cities of South Asia: the CARRS studyKavita Singh, Dimple Kondal, Roopa Shivashankar, et al.
Clinical Transplantation|May 19, 2018
Evaluation of current strategies for surveillance and management of donor-specific antibodies: Single-center studyDaniel Sullivan, Chul Ahn, Ang Gao, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 3, 2006
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute TrialsLalitha K Shankar, John M Hoffman, Steve Bacharach, et al.
The International Journal of Eating Disorders|February 27, 2021
Registered report: Initial development and validation of the eating disorders safety behavior scaleErin E Reilly, Brittany Bohrer, Daniel Sullivan, et al.
Nature Human Behaviour|May 18, 2019
Understanding cooperation through fitness interdependenceAthena Aktipis, Lee Cronk, Joe Alcock, et al.
Investigational New Drugs|March 22, 2016
Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancerShivaani Kummar, James L Wade, Amit M Oza, et al.
Leukemia & Lymphoma|July 19, 2016
Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomideDana E Rollison, Rami Komrokji, Ji-Hyun Lee, et al.
Cancer Chemotherapy and Pharmacology|August 11, 2012
A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancerRichard M Lush, Amita Patnaik, Daniel Sullivan, et al.
Pageof 13

Showing results (101-110 of 130) with videos related to

Sort By:
Pageof 13
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 28, 2010
A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxisJanelle Perkins, Teresa Field, Jongphil Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2007
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational studyPamela Münster, Douglas Marchion, Elona Bicaku, et al.
BMJ Open|October 18, 2017
Health-related quality of life variations by sociodemographic factors and chronic conditions in three metropolitan cities of South Asia: the CARRS studyKavita Singh, Dimple Kondal, Roopa Shivashankar, et al.
Clinical Transplantation|May 19, 2018
Evaluation of current strategies for surveillance and management of donor-specific antibodies: Single-center studyDaniel Sullivan, Chul Ahn, Ang Gao, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 3, 2006
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute TrialsLalitha K Shankar, John M Hoffman, Steve Bacharach, et al.
The International Journal of Eating Disorders|February 27, 2021
Registered report: Initial development and validation of the eating disorders safety behavior scaleErin E Reilly, Brittany Bohrer, Daniel Sullivan, et al.
Nature Human Behaviour|May 18, 2019
Understanding cooperation through fitness interdependenceAthena Aktipis, Lee Cronk, Joe Alcock, et al.
Investigational New Drugs|March 22, 2016
Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancerShivaani Kummar, James L Wade, Amit M Oza, et al.
Leukemia & Lymphoma|July 19, 2016
Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomideDana E Rollison, Rami Komrokji, Ji-Hyun Lee, et al.
Cancer Chemotherapy and Pharmacology|August 11, 2012
A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancerRichard M Lush, Amita Patnaik, Daniel Sullivan, et al.
Pageof 13